Phage-Derived Enzyme Targets E. faecalis Biofilms to Mitigate Acute Graft-Versus-Host Disease
In a recent study published in the journal Nature, our [...]
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, concludes: “We [...]
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
“Myeloproliferative neoplasms, including ET and PV, are chronic blood diseases [...]
Micro Medical Solutions | Achieves Milestone with 200th Enrollment in HEAL Registry
reg Sullivan, CEO of Micro Medical Solutions. “This milestone is [...]
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
The VenusP-Valve PROTEUS STUDY, abbreviated from Evaluation of the PerfoRmance [...]
Pfizer Reports | ELREXFIO ™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
“These compelling overall survival data support the clinical benefit ELREXFIO [...]
Updated Phase 2 CAPTIVATE Study Results
“After more than five years, the CAPTIVATE study findings confirm [...]
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease | Presented at the European Hematology Association (EHA) Annual Congress
“These data confirm the observations from our prior clinical readouts [...]
Innovent Biologics Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
Dr. Hui Zhou, Senior Vice President of Innovent, stated: “IBI363, [...]
Positive 6 Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
Favorable patient outcomes from the TANDEM I first-in-human clinical trial [...]